These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24106334)

  • 1. Clonidine normalizes levels of P50 gating in patients with schizophrenia on stable medication.
    Oranje B; Glenthøj BY
    Schizophr Bull; 2014 Sep; 40(5):1022-9. PubMed ID: 24106334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication.
    Oranje B; Glenthøj BY
    Schizophr Bull; 2013 May; 39(3):684-91. PubMed ID: 22750632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication.
    Kruiper C; Glenthøj BY; Oranje B
    Neuropsychopharmacology; 2019 May; 44(6):1062-1067. PubMed ID: 30797222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial.
    Kruiper C; Sommer IEC; Koster M; Bakker PR; Durston S; Oranje B
    Schizophr Res; 2023 May; 255():148-154. PubMed ID: 36989672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
    J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment.
    Oranje B; Aggernaes B; Rasmussen H; Ebdrup BH; Glenthøj BY
    Schizophr Bull; 2013 Mar; 39(2):472-80. PubMed ID: 22241164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.
    Hong X; Chan RC; Zhuang X; Jiang T; Wan X; Wang J; Xiao B; Zhou H; Jiang L; Weng B
    Schizophr Res; 2009 Mar; 108(1-3):151-7. PubMed ID: 19106034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of acute exogenous melatonin on P50 suppression in healthy male volunteers stratified for low and high gating levels.
    Ucar E; Lehtinen EK; Glenthøj BY; Oranje B
    J Psychopharmacol; 2012 Aug; 26(8):1113-8. PubMed ID: 22331175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
    Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR
    Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline dependency of nicotine's sensory gating actions: similarities and differences in low, medium and high P50 suppressors.
    Knott V; de la Salle S; Smith D; Phillipe T; Dort H; Choueiry J; Impey D
    J Psychopharmacol; 2013 Sep; 27(9):790-800. PubMed ID: 23744798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression.
    Knott V; Smith D; de la Salle S; Impey D; Choueiry J; Beaudry E; Smith M; Saghir S; Ilivitsky V; Labelle A
    J Psychopharmacol; 2014 Dec; 28(12):1095-108. PubMed ID: 25315828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
    Int J Psychophysiol; 2019 Nov; 145():70-82. PubMed ID: 30790597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study.
    Winterer G; Gallinat J; Brinkmeyer J; Musso F; Kornhuber J; Thuerauf N; Rujescu D; Favis R; Sun Y; Franc MA; Ouwerkerk-Mahadevan S; Janssens L; Timmers M; Streffer JR
    Neuropharmacology; 2013 Jan; 64():197-204. PubMed ID: 22766391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P50 suppression deficits and psychopathology in Han Chinese patients with schizophrenia.
    Zhu XL; Tan SP; Wang ZR; Zhang JG; Li D; Fan FM; Zhao YL; Zou YZ; Tan YL; Yang F; Zhang XY
    Neurosci Lett; 2017 Jul; 653():346-350. PubMed ID: 28606770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of acute serotonin and dopamine depletion on prepulse inhibition and p50 suppression measures of sensorimotor and sensory gating in humans.
    Mann C; Croft RJ; Scholes KE; Dunne A; O'Neill BV; Leung S; Copolov D; Phan KL; Nathan PJ
    Neuropsychopharmacology; 2008 Jun; 33(7):1653-66. PubMed ID: 17895917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single high dose of escitalopram disrupts sensory gating and habituation, but not sensorimotor gating in healthy volunteers.
    Oranje B; Wienberg M; Glenthoj BY
    Psychiatry Res; 2011 Apr; 186(2-3):431-6. PubMed ID: 20971512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The separate and combined effects of monoamine oxidase inhibition and nicotine on P50 sensory gating.
    Smith DM; Fisher D; Blier P; Illivitsky V; Knott V
    Psychopharmacology (Berl); 2015 Jun; 232(11):1911-20. PubMed ID: 25466703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of cognitive and P50 suppression deficits in chronic patients with schizophrenia.
    Xia L; Wang D; Wang J; Xu H; Huo L; Tian Y; Dai Q; Wei S; Wang W; Zhang G; Du X; Jia Q; Zhu X; Wang L; Tang W; Zhang XY
    Clin Neurophysiol; 2020 Mar; 131(3):725-733. PubMed ID: 32000073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients.
    Boutros NN; Brockhaus-Dumke A; Gjini K; Vedeniapin A; Elfakhani M; Burroughs S; Keshavan M
    Schizophr Res; 2009 Sep; 113(2-3):339-46. PubMed ID: 19524407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P50 gating at acute and post-acute phases of first-episode schizophrenia.
    Devrim-Uçok M; Keskin-Ergen HY; Uçok A
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1952-6. PubMed ID: 18929611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.